Vascular Endothelial Growth Factor A (VEGF-A) stands at the intersection of oncology and ophthalmology as the central mediator of pathological angiogenesis. From bevacizumab's landmark 2004 approval to faricimab's bispecific VEGF-A/Ang-2 format, the field is in active transition — driven by the patent cliff of first-generation biologics, ultra-high-affinity trap designs, and high-durability formulations. MAbSilico engineers differentiated next-generation anti-VEGF-A candidates across mAb, Fab, scFv and bispecific formats.
VEGF-A is the primary driver of vascular endothelial cell proliferation, migration and survival. Its overproduction drives two major pathological contexts: tumor angiogenesis in oncology and neovascular retinal diseases in ophthalmology.
The VEGF-A gene consists of eight exons that undergo alternative splicing to generate multiple isoforms. VEGF-A₁₆₅ is the most prevalent and biologically significant — possessing a heparin-binding domain that facilitates ECM interaction and engagement with co-receptors like NRP1. VEGF-A signals through two high-affinity tyrosine kinase receptors: VEGFR-1 (Flt-1), a high-affinity decoy receptor (Kd ~10-20 pM) with weak kinase activity, and VEGFR-2 (KDR/Flk-1), the principal signaling receptor for angiogenesis and vascular permeability.
Binding of VEGF-A to VEGFR-2 induces receptor dimerization and autophosphorylation, triggering three downstream pathways critical for neovascularization: the PI3K/AKT pathway (endothelial cell survival and eNOS activation → vasodilation and permeability), the MAPK/ERK pathway (Ras/Raf/MEK/ERK → DNA synthesis and cell proliferation), and the p38 MAPK pathway (actin cytoskeletal reorganization and tip cell migration during angiogenic sprouting).
| Context | Pathology | Mechanism |
|---|---|---|
| Ophthalmology | nAMD, DME, RVO | Local VEGF-A overproduction → growth of immature, leaky sub-retinal vessels disrupting tissue architecture |
| Oncology | CRC, NSCLC, RCC, GBM | Tumors exploit VEGF-A to overcome hypoxic metabolic limits — establishing vascular networks for growth and metastasis |
Patent cliff transition: Bevacizumab (2004) and ranibizumab (2006) biosimilars are entering the market. The next generation — ultra-high-affinity traps, high-durability scFvs and VEGF+Ang-2 bispecifics — defines the new differentiation frontier.
Each successive generation of anti-VEGF agents has been defined by a structural innovation — from bevacizumab's full IgG to aflibercept's receptor trap to brolucizumab's miniaturized scFv to faricimab's dual-antigen bispecific approach.
| Therapeutic Agent | Molecular Structure | Primary Targets | MW (kDa) | Key Innovation |
|---|---|---|---|---|
| Bevacizumab | Humanized IgG1 mAb | VEGF-A (all isoforms) | ~149 | First anti-angiogenic mAb |
| Ranibizumab | Humanized Fab fragment | VEGF-A | ~48 | Ocular miniaturization + affinity maturation |
| Aflibercept | VEGFR1/2 Fusion Trap | VEGF-A, VEGF-B, PlGF | ~115 | Pan-ligand ultra-high affinity (Kd ~0.5 pM) |
| Brolucizumab | scFv (~26 kDa) | VEGF-A | ~26 | Extreme miniaturization → high molar dose/injection |
| Faricimab | CrossMAb Bispecific IgG1 | VEGF-A + Ang-2 | ~150 | Dual angiogenesis + vascular stability targeting |
Our 6-step workflow navigates VEGF-A's dual-indication landscape — engineering candidates optimized for oncology (systemic IgG, Fc-mediated half-life) or ophthalmology (miniaturized Fab/scFv, intraocular penetration) from the ground up.
From ultra-high-affinity trap designs to VEGF+Ang-2 bispecifics and miniaturized scFv for ophthalmology — MAbSilico engineers differentiated VEGF-A candidates for the post-bevacizumab era.